FDA grants BTD for Venclexta in combination with azacitidine to treat patients with myelodysplastic syndromes Read more
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive MS Read more
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers Read more
Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia Read more
US DOJ permits six drug makers to share info about COVID-19 MAb treatments to expedite production Read more